- Home
- XTKG vs PMVP Comparison
XTKG vs PMVP Comparison
Compare XTKG & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XTKG
- PMVP
- Stock Information
- Founded
- XTKG 1997
- PMVP 2013
- Country
- XTKG Singapore
- PMVP United States
- Employees
- XTKG N/A
- PMVP N/A
- Industry
- XTKG
- PMVP Medicinal Chemicals and Botanical Products
- Sector
- XTKG
- PMVP Health Care
- Exchange
- XTKG NYSE
- PMVP Nasdaq
- Market Cap
- XTKG 63.1M
- PMVP 62.3M
- IPO Year
- XTKG 2019
- PMVP 2020
- Fundamental
- Price
- XTKG $1.80
- PMVP $1.41
- Analyst Decision
- XTKG
- PMVP Strong Buy
- Analyst Count
- XTKG 0
- PMVP 1
- Target Price
- XTKG N/A
- PMVP $5.00
- AVG Volume (30 Days)
- XTKG 59.6K
- PMVP 338.2K
- Earning Date
- XTKG 08-05-2025
- PMVP 08-07-2025
- Dividend Yield
- XTKG N/A
- PMVP N/A
- EPS Growth
- XTKG N/A
- PMVP N/A
- EPS
- XTKG N/A
- PMVP N/A
- Revenue
- XTKG $11,611,442.00
- PMVP N/A
- Revenue This Year
- XTKG N/A
- PMVP N/A
- Revenue Next Year
- XTKG N/A
- PMVP N/A
- P/E Ratio
- XTKG N/A
- PMVP N/A
- Revenue Growth
- XTKG N/A
- PMVP N/A
- 52 Week Low
- XTKG $0.53
- PMVP $0.81
- 52 Week High
- XTKG $9.40
- PMVP $1.82
- Technical
- Relative Strength Index (RSI)
- XTKG 54.02
- PMVP 66.50
- Support Level
- XTKG $1.73
- PMVP $1.27
- Resistance Level
- XTKG $1.90
- PMVP $1.50
- Average True Range (ATR)
- XTKG 0.15
- PMVP 0.08
- MACD
- XTKG -0.00
- PMVP 0.01
- Stochastic Oscillator
- XTKG 73.53
- PMVP 70.97
About XTKG X3 HOLDINGS CO LTD
X3 Holdings Co Ltd is company which is responsible for globally providing of Technology Solutions and Services across Diverse Industries. It generates revenue from service lines: Application development services; Consulting and technical support services; Subscription services; Trading; and Others, of which maximum revenue is derived from Application development services. Geographically, all of the company's revenue is derived from PRC.
About PMVP PMV Pharmaceuticals Inc.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. Its pipeline rezatapopt PYNNACLE, rezatapopt and azacitidine, rezatapopt (PC14586), and PMV-586-101.